Trials / Completed
CompletedNCT04102150
Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
A Phase 2, Multicenter, Open-label, Single-arm Study of Valemetostat Tosylate (DS-3201b) in Patients With Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valemetostat Tosylate | Once a day, 200 mg, oral administration |
Timeline
- Start date
- 2019-11-21
- Primary completion
- 2021-04-24
- Completion
- 2024-10-27
- First posted
- 2019-09-25
- Last updated
- 2025-02-10
Locations
24 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04102150. Inclusion in this directory is not an endorsement.